• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

    4.195 -0.055 (-1.29%)
    Streaming Delayed Price Updated: 3:01 PM EDT, Apr 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,983,540
    Open 4.240
    Bid (Size) 4.190 (2,500)
    Ask (Size) 4.200 (2,200)
    Prev. Close 4.250
    Today's Range 4.120 - 4.310
    52wk Range 2.940 - 5.100
    Shares Outstanding 99,161,234
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire

    Performance

    YTD
    -12.1%
    -12.1%
    1 Month
    -2.7%
    -2.7%
    3 Month
    +0.8%
    +0.8%
    6 Month
    -2.0%
    -2.0%
    1 Year
    +29.5%
    +29.5%

    More News

    Read More
    News headline image
    Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
    Via Stocktwits
    Topics Intellectual Property
    ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
    Via Finterra
    Topics Initial Public Offering Intellectual Property Lawsuit
    Get insights into the top gainers and losers of Friday's pre-market session. ↗
    Via Chartmill
    News headline image
    Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
    Via Finterra
    Topics Initial Public Offering Intellectual Property
    News headline image
    The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
    Via MarketMinute
    Topics Economy Intellectual Property World Trade
    News headline image
    Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
    Via PredictStreet
    Topics Initial Public Offering Intellectual Property
    News headline image
    Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗
    Via Chartmill
    News headline image
    Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus (ABUS) Q2 Revenue Surges 529% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
    From Arbutus Biopharma Corporation
    Via GlobeNewswire

    Frequently Asked Questions

    Is Arbutus Biopharma Corporation - Common Stock publicly traded?
    Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.
    What exchange does Arbutus Biopharma Corporation - Common Stock trade on?
    Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?
    The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market
    What is the current price of Arbutus Biopharma Corporation - Common Stock?
    The current price of Arbutus Biopharma Corporation - Common Stock is 4.195
    When was Arbutus Biopharma Corporation - Common Stock last traded?
    The last trade of Arbutus Biopharma Corporation - Common Stock was at 04/24/26 03:01 PM ET
    What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?
    The market capitalization of Arbutus Biopharma Corporation - Common Stock is 415.98M
    How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?
    Arbutus Biopharma Corporation - Common Stock has 416M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.